510 related articles for article (PubMed ID: 31208393)
1. Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial.
Park CH; Lee HK; Kim MK; Kim EC; Kim JY; Kim TI; Kim HK; Song JS; Yoon KC; Lee DH; Chung TY; Choi CY; Kim HS
BMC Ophthalmol; 2019 Jun; 19(1):131. PubMed ID: 31208393
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye.
Park CH; Kim MK; Kim EC; Kim JY; Kim TI; Kim HK; Song JS; Yoon KC; Lee DH; Lee HK; Chung TY; Choi CY; Kim HS
Korean J Ophthalmol; 2019 Aug; 33(4):343-352. PubMed ID: 31389210
[TBL] [Abstract][Full Text] [Related]
3. The Efficacy of Diquafosol Ophthalmic Solution in Non-Sjögren and Sjögren Syndrome Dry Eye Patients Unresponsive to Artificial Tear.
Jeon HS; Hyon JY
J Ocul Pharmacol Ther; 2016 Sep; 32(7):463-8. PubMed ID: 27294831
[TBL] [Abstract][Full Text] [Related]
4. Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition.
Shigeyasu C; Yamada M; Akune Y; Tsubota K
Jpn J Ophthalmol; 2015 Nov; 59(6):415-20. PubMed ID: 26310103
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Topical Cyclosporine and Diquafosol Treatment in Dry Eye.
Yang JM; Choi W; Kim N; Yoon KC
Optom Vis Sci; 2015 Sep; 92(9):e296-302. PubMed ID: 26107023
[TBL] [Abstract][Full Text] [Related]
6. Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye: A Pilot Study.
Zhang Q; Zhang H; Qin G; Wu Y; Song Y; Yang L; Yu S; He X; Moore JE; Moutari S; Palme C; Xu L; He W; Pazo EE
J Ocul Pharmacol Ther; 2022 Mar; 38(2):133-140. PubMed ID: 35049373
[No Abstract] [Full Text] [Related]
7. Comparing two mucin secretagogues for the treatment of dry eye disease: a prospective randomized crossover trial.
Jin Y; Seo KY; Kim SW
Sci Rep; 2024 Jun; 14(1):13306. PubMed ID: 38858411
[TBL] [Abstract][Full Text] [Related]
8. Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's syndrome.
Yokoi N; Sonomura Y; Kato H; Komuro A; Kinoshita S
Eye (Lond); 2015 Sep; 29(9):1204-12. PubMed ID: 26160526
[TBL] [Abstract][Full Text] [Related]
9. Effects of Diquafosol Ophthalmic Solution on Quality of Life in Dry Eye Assessed Using the Dry Eye-Related Quality-of-Life Score Questionnaire: Effectiveness in Patients While Reading and Using Visual Display Terminals.
Utsunomiya T; Kawahara A; Hanada K; Yoshida A
Cornea; 2017 Aug; 36(8):908-914. PubMed ID: 28542084
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Topical 3% Diquafosol Ophthalmic Solution for the Treatment of Multifactorial Dry Eye Disease: Meta-Analysis of Randomized Clinical Trials.
Nam K; Kim HJ; Yoo A
Ophthalmic Res; 2019; 61(4):188-198. PubMed ID: 30654362
[TBL] [Abstract][Full Text] [Related]
11. Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial.
Park DH; Chung JK; Seo DR; Lee SJ
Am J Ophthalmol; 2016 Mar; 163():122-131.e2. PubMed ID: 26685791
[TBL] [Abstract][Full Text] [Related]
12. Additive Effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops.
Hwang HS; Sung YM; Lee WS; Kim EC
Cornea; 2014 Sep; 33(9):935-41. PubMed ID: 25055152
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Combined Tear Film Therapy in Patients with Evaporative Dry Eye with Short Tear Film Breakup Time.
Kim YH; Kang YS; Lee HS; Choi W; You IC; Yoon KC
J Ocul Pharmacol Ther; 2017 Oct; 33(8):635-643. PubMed ID: 28846481
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease.
Mun Y; Kwon JW; Oh JY
BMC Ophthalmol; 2018 Sep; 18(1):237. PubMed ID: 30185156
[TBL] [Abstract][Full Text] [Related]
15. Effect of diquafosol tetrasodium 3% on the conjunctival surface and clinical findings after cataract surgery in patients with dry eye.
Cui L; Li Y; Lee HS; Yang JM; Choi W; Yoon KC
Int Ophthalmol; 2018 Oct; 38(5):2021-2030. PubMed ID: 28822028
[TBL] [Abstract][Full Text] [Related]
16. Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye.
Yamane M; Ogawa Y; Fukui M; Kamoi M; Saijo-Ban Y; Yaguchi S; Mukai S; Kawakita T; Simmura S; Tsubota K
Optom Vis Sci; 2015 Apr; 92(4 Suppl 1):S25-32. PubMed ID: 25785527
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye.
Koh S; Ikeda C; Takai Y; Watanabe H; Maeda N; Nishida K
Jpn J Ophthalmol; 2013 Sep; 57(5):440-6. PubMed ID: 23740285
[TBL] [Abstract][Full Text] [Related]
18. Vitamin B12 deficiency evaluation and treatment in severe dry eye disease with neuropathic ocular pain.
Ozen S; Ozer MA; Akdemir MO
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1173-1177. PubMed ID: 28299439
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of topical diquafosol for the treatment of dry eye disease: An updated meta-analysis of randomized controlled trials.
Liu S; Yang G; Li Q; Tang S
Indian J Ophthalmol; 2023 Apr; 71(4):1304-1315. PubMed ID: 37026262
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of topical cyclosporine 0.05% and osmoprotective lubricating eye drops in treating dry eye disease and inflammation.
Mullick R; Annavajjhala S; Thakur P; Mohapatra A; Shetty R; D'Souza S
Indian J Ophthalmol; 2021 Dec; 69(12):3473-3477. PubMed ID: 34826977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
